Capmatinib Completed Phase 2 Trials for NTRK1 Fusion Positive / Stage III Cutaneous Melanoma AJCC v7 / NTRK2 Fusion Positive / Stage IIIC Cutaneous Melanoma AJCC v7 / ALK Fusion Protein Expression / MET Fusion Gene Positive / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7 / NRAS wt Allele / BRAF wt Allele / RET Fusion Positive / Stage IIIB Cutaneous Melanoma AJCC v7 / NTRK3 Fusion Positive / Melanoma / ROS1 Fusion Positive / Invasive Skin Melanoma Treatment